Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphatic System | 4 | 1996 | 54 | 0.450 |
Why?
|
| Esophageal Perforation | 3 | 1996 | 18 | 0.230 |
Why?
|
| Dental Care for Chronically Ill | 1 | 2003 | 4 | 0.190 |
Why?
|
| Muscle Contraction | 4 | 1996 | 256 | 0.180 |
Why?
|
| Trachea | 3 | 1996 | 245 | 0.170 |
Why?
|
| Bronchi | 3 | 1996 | 225 | 0.170 |
Why?
|
| Social Support | 1 | 2003 | 233 | 0.160 |
Why?
|
| Muscle, Smooth | 3 | 1996 | 300 | 0.150 |
Why?
|
| Histamine | 1 | 1996 | 116 | 0.120 |
Why?
|
| Nitric Oxide | 2 | 1996 | 281 | 0.120 |
Why?
|
| Receptors, Endothelin | 1 | 1996 | 12 | 0.120 |
Why?
|
| Endothelins | 1 | 1996 | 26 | 0.120 |
Why?
|
| Endothelium, Lymphatic | 1 | 1996 | 11 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2003 | 1073 | 0.120 |
Why?
|
| Swine | 4 | 1996 | 588 | 0.100 |
Why?
|
| omega-N-Methylarginine | 3 | 1996 | 17 | 0.090 |
Why?
|
| In Vitro Techniques | 3 | 1996 | 948 | 0.080 |
Why?
|
| Arginine | 2 | 1996 | 141 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 1996 | 641 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2003 | 36 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 1997 | 884 | 0.030 |
Why?
|
| Postoperative Complications | 4 | 1997 | 2562 | 0.030 |
Why?
|
| Histamine Agonists | 1 | 1996 | 2 | 0.030 |
Why?
|
| Stomach Diseases | 1 | 1997 | 18 | 0.030 |
Why?
|
| Histamine Antagonists | 1 | 1996 | 14 | 0.030 |
Why?
|
| Esophageal Diseases | 1 | 1997 | 25 | 0.030 |
Why?
|
| Esophagectomy | 1 | 1997 | 92 | 0.030 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 1996 | 11 | 0.030 |
Why?
|
| Receptor, Endothelin A | 1 | 1996 | 21 | 0.030 |
Why?
|
| Mediastinum | 1 | 1996 | 43 | 0.030 |
Why?
|
| Male | 9 | 1997 | 44557 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1996 | 123 | 0.030 |
Why?
|
| Esophagus | 1 | 1996 | 113 | 0.030 |
Why?
|
| Animals | 4 | 1996 | 28155 | 0.030 |
Why?
|
| Fundoplication | 1 | 1996 | 73 | 0.030 |
Why?
|
| Esophageal Achalasia | 1 | 1996 | 61 | 0.030 |
Why?
|
| Catheterization | 1 | 1996 | 218 | 0.030 |
Why?
|
| Oligopeptides | 1 | 1996 | 191 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 1995 | 24 | 0.030 |
Why?
|
| Piperidines | 1 | 1996 | 165 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1995 | 356 | 0.030 |
Why?
|
| Dinoprost | 1 | 1994 | 27 | 0.030 |
Why?
|
| Lymph | 1 | 1994 | 14 | 0.030 |
Why?
|
| Mesentery | 1 | 1994 | 46 | 0.030 |
Why?
|
| Survival Rate | 2 | 1995 | 1948 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 1995 | 195 | 0.030 |
Why?
|
| Aged | 6 | 1997 | 20434 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 1997 | 7061 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 1995 | 217 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 1995 | 344 | 0.020 |
Why?
|
| Female | 8 | 1997 | 48702 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1996 | 1799 | 0.020 |
Why?
|
| Recurrence | 1 | 1995 | 1190 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 1997 | 10164 | 0.020 |
Why?
|
| Child | 1 | 2003 | 7355 | 0.020 |
Why?
|
| Adolescent | 4 | 1997 | 9606 | 0.020 |
Why?
|
| Patient Selection | 1 | 1995 | 690 | 0.020 |
Why?
|
| Humans | 8 | 2003 | 93515 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1995 | 1077 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1995 | 1173 | 0.020 |
Why?
|
| Middle Aged | 6 | 1997 | 27573 | 0.020 |
Why?
|
| Adult | 5 | 1997 | 27918 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 1996 | 3830 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 1997 | 43 | 0.010 |
Why?
|
| Heartburn | 1 | 1996 | 10 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1997 | 292 | 0.010 |
Why?
|
| Emergencies | 1 | 1996 | 122 | 0.010 |
Why?
|
| Risk Factors | 2 | 1997 | 5899 | 0.010 |
Why?
|
| Esophagogastric Junction | 1 | 1995 | 35 | 0.010 |
Why?
|
| Spirometry | 1 | 1995 | 77 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 1996 | 126 | 0.010 |
Why?
|
| Leucovorin | 1 | 1995 | 200 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 1995 | 231 | 0.010 |
Why?
|
| Gastroesophageal Reflux | 1 | 1996 | 121 | 0.010 |
Why?
|
| Morbidity | 1 | 1995 | 162 | 0.010 |
Why?
|
| Pain Management | 1 | 1996 | 180 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1996 | 406 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1995 | 314 | 0.010 |
Why?
|
| Models, Statistical | 1 | 1997 | 585 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1995 | 235 | 0.010 |
Why?
|
| Pain | 1 | 1996 | 414 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1995 | 524 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1995 | 512 | 0.010 |
Why?
|
| Remission Induction | 1 | 1995 | 738 | 0.010 |
Why?
|
| Cisplatin | 1 | 1995 | 568 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1995 | 283 | 0.010 |
Why?
|
| Logistic Models | 1 | 1995 | 1243 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1995 | 1723 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1995 | 1713 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 1995 | 2017 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1995 | 2544 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 1996 | 9099 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1995 | 2365 | 0.000 |
Why?
|